By Mark L. Ratner
It was just two years ago that Immunex Corp. (now a division of Amgen Inc. ) told the...
The handful of firms with established bioprocessing capabilities has dominating advantages in antibody drug development. Because process varies little from one antibody to another, they can wait for and quickly pounce on fast-follower opportunities, expanding production capacity in a modular fashion as demand requires--and in this way minimize target risk. Meanwhile, smaller companies, which cannot buy their way into the game nor compete in the more mature world of fast followers, are using their technology development expertise to come up with good drugs against novel targets in diseases where no antibody treatments currently exist, hoping that the novelty of the resulting products will give them the kind of leverage they haven't been able to get from platform dealmaking.
By Mark L. Ratner
It was just two years ago that Immunex Corp. (now a division of Amgen Inc. ) told the...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.